Fundies. English
Segment disclosures
Company overviewELITE PHARMACEUTICALS INC /NV/
Each reported dimension combination stays separate. Revenue and operating income are shown as reported, with their dates and sources.
Revenue · Reported segment facts
20 dimension combinations 264 retained observations 43 reported periods
Counts describe retained dimensioned rows only. Periods and members can change across reports, and this view does not infer missing values or expected segment totals.
Licensing Fees · Abbreviated New Drug Applications
Fees · Statement Business Segments
Source dimensions
eltp:FeesAxis=eltp:LicensingFeesMember;us-gaap:StatementBusinessSegmentsAxis=eltp:AbbreviatedNewDrugApplicationsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2020-04-01 – 2021-03-31 | 4217272 | USD | 20210614 | Open filing evidence |
| 2020-10-01 – 2020-12-31 | 1196711 | USD | 20210216 | Open filing evidence |
| 2020-04-01 – 2020-12-31 | 3159217 | USD | 20210216 | Open filing evidence |
| 2020-07-01 – 2020-09-30 | 1227168 | USD | 20201116 | Open filing evidence |
| 2020-04-01 – 2020-09-30 | 1962506 | USD | 20201116 | Open filing evidence |
| 2019-04-01 – 2020-03-31 | 2468591 | USD | 20210614 | Open filing evidence |
| 2019-10-01 – 2019-12-31 | 1050392 | USD | 20210216 | Open filing evidence |
| 2019-04-01 – 2019-12-31 | 1447915 | USD | 20210216 | Open filing evidence |
| 2019-07-01 – 2019-09-30 | 215641 | USD | 20201116 | Open filing evidence |
| 2019-04-01 – 2019-09-30 | 397523 | USD | 20201116 | Open filing evidence |
Licensing Fees · New Drug Applications
Fees · Statement Business Segments
Source dimensions
eltp:FeesAxis=eltp:LicensingFeesMember;us-gaap:StatementBusinessSegmentsAxis=eltp:NewDrugApplicationsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2020-04-01 – 2021-03-31 | 166167 | USD | 20210614 | Open filing evidence |
| 2020-04-01 – 2020-12-31 | 166167 | USD | 20210216 | Open filing evidence |
| 2020-04-01 – 2020-09-30 | 166167 | USD | 20201116 | Open filing evidence |
| 2019-04-01 – 2020-03-31 | 1000000 | USD | 20210614 | Open filing evidence |
| 2019-10-01 – 2019-12-31 | 250000 | USD | 20210216 | Open filing evidence |
| 2019-04-01 – 2019-12-31 | 750000 | USD | 20210216 | Open filing evidence |
| 2019-07-01 – 2019-09-30 | 250000 | USD | 20201116 | Open filing evidence |
| 2019-04-01 – 2019-09-30 | 500000 | USD | 20201116 | Open filing evidence |
Manufacturing Fees · Abbreviated New Drug Applications
Fees · Statement Business Segments
Source dimensions
eltp:FeesAxis=eltp:ManufacturingFeesMember;us-gaap:StatementBusinessSegmentsAxis=eltp:AbbreviatedNewDrugApplicationsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2020-04-01 – 2021-03-31 | 20997310 | USD | 20210614 | Open filing evidence |
| 2020-10-01 – 2020-12-31 | 4849871 | USD | 20210216 | Open filing evidence |
| 2020-04-01 – 2020-12-31 | 17659834 | USD | 20210216 | Open filing evidence |
| 2020-07-01 – 2020-09-30 | 6172724 | USD | 20201116 | Open filing evidence |
| 2020-04-01 – 2020-09-30 | 12809963 | USD | 20201116 | Open filing evidence |
| 2019-04-01 – 2020-03-31 | 14526048 | USD | 20210614 | Open filing evidence |
| 2019-10-01 – 2019-12-31 | 3754721 | USD | 20210216 | Open filing evidence |
| 2019-04-01 – 2019-12-31 | 10851425 | USD | 20210216 | Open filing evidence |
| 2019-07-01 – 2019-09-30 | 4169346 | USD | 20201116 | Open filing evidence |
| 2019-04-01 – 2019-09-30 | 7096704 | USD | 20201116 | Open filing evidence |
License And Service · Abbreviated New Drug Applications
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=us-gaap:LicenseAndServiceMember;us-gaap:StatementBusinessSegmentsAxis=eltp:AbbreviatedNewDrugApplicationsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2018-10-01 – 2018-12-31 | 335479 | USD | 20200210 | Open filing evidence |
| 2018-07-01 – 2018-09-30 | 306562 | USD | 20181109 | Open filing evidence |
| 2017-10-01 – 2017-12-31 | 201628 | USD | 20190211 | Open filing evidence |
| 2017-07-01 – 2017-09-30 | 307354 | USD | 20181109 | Open filing evidence |
License And Service · New Drug Applications
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=us-gaap:LicenseAndServiceMember;us-gaap:StatementBusinessSegmentsAxis=eltp:NewDrugApplicationsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2018-10-01 – 2018-12-31 | 250000 | USD | 20200210 | Open filing evidence |
| 2018-07-01 – 2018-09-30 | 250000 | USD | 20181109 | Open filing evidence |
| 2017-10-01 – 2017-12-31 | 250000 | USD | 20190211 | Open filing evidence |
| 2017-07-01 – 2017-09-30 | 250000 | USD | 20181109 | Open filing evidence |
Manufactured Product Other · Abbreviated New Drug Applications
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=us-gaap:ManufacturedProductOtherMember;us-gaap:StatementBusinessSegmentsAxis=eltp:AbbreviatedNewDrugApplicationsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2018-10-01 – 2018-12-31 | 2108487 | USD | 20200210 | Open filing evidence |
| 2018-07-01 – 2018-09-30 | 806487 | USD | 20181109 | Open filing evidence |
| 2017-10-01 – 2017-12-31 | 2083826 | USD | 20190211 | Open filing evidence |
| 2017-07-01 – 2017-09-30 | 1066227 | USD | 20181109 | Open filing evidence |
Branded Products Nda · Business Segment
Product Or Service · Statement Business Segments
Source dimensions
us-gaap:ProductOrServiceAxis=eltp:BrandedProductsNdaMember;us-gaap:StatementBusinessSegmentsAxis=eltp:BusinessSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2017-04-01 – 2018-03-31 | 1000000 | USD | 20180614 | Open filing evidence |
| 2017-10-01 – 2017-12-31 | 250000 | USD | 20180209 | Open filing evidence |
| 2017-07-01 – 2017-09-30 | 250000 | USD | 20171109 | Open filing evidence |
| 2017-04-01 – 2017-06-30 | 250000 | USD | 20170809 | Open filing evidence |
| 2016-04-01 – 2017-03-31 | 1000000 | USD | 20180614 | Open filing evidence |
| 2016-10-01 – 2016-12-31 | 250000 | USD | 20180209 | Open filing evidence |
| 2016-04-01 – 2016-12-31 | 750000 | USD | 20170209 | Open filing evidence |
| 2016-07-01 – 2016-09-30 | 250000 | USD | 20171109 | Open filing evidence |
| 2016-04-01 – 2016-09-30 | 500000 | USD | 20161109 | Open filing evidence |
| 2016-04-01 – 2016-06-30 | 250000 | USD | 20170809 | Open filing evidence |
| 2015-04-01 – 2016-03-31 | 3333333 | USD | 20180614 | Open filing evidence |
| 2015-10-01 – 2015-12-31 | 250000 | USD | 20170209 | Open filing evidence |
| 2015-04-01 – 2015-12-31 | 583333 | USD | 20170209 | Open filing evidence |
| 2015-07-01 – 2015-09-30 | 250000 | USD | 20161109 | Open filing evidence |
| 2015-04-01 – 2015-09-30 | 333333 | USD | 20161109 | Open filing evidence |
| 2014-04-01 – 2015-03-31 | 0 | USD | 20170614 | Open filing evidence |
Generic Products Anda · Business Segment
Product Or Service · Statement Business Segments
Source dimensions
us-gaap:ProductOrServiceAxis=eltp:GenericProductsAndaMember;us-gaap:StatementBusinessSegmentsAxis=eltp:BusinessSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2017-04-01 – 2018-03-31 | 6458711 | USD | 20180614 | Open filing evidence |
| 2017-10-01 – 2017-12-31 | 2285454 | USD | 20180209 | Open filing evidence |
| 2017-07-01 – 2017-09-30 | 1373581 | USD | 20171109 | Open filing evidence |
| 2017-04-01 – 2017-09-30 | 2826351 | USD | 20171109 | Open filing evidence |
| 2017-04-01 – 2017-06-30 | 1452770 | USD | 20170809 | Open filing evidence |
| 2016-04-01 – 2017-03-31 | 8637715 | USD | 20180614 | Open filing evidence |
| 2016-10-01 – 2016-12-31 | 2080649 | USD | 20180209 | Open filing evidence |
| 2016-04-01 – 2016-12-31 | 7537493 | USD | 20170209 | Open filing evidence |
| 2016-07-01 – 2016-09-30 | 2435698 | USD | 20171109 | Open filing evidence |
| 2016-04-01 – 2016-09-30 | 5456844 | USD | 20171109 | Open filing evidence |
| 2016-04-01 – 2016-06-30 | 3021146 | USD | 20170809 | Open filing evidence |
| 2015-04-01 – 2016-03-31 | 9164999 | USD | 20180614 | Open filing evidence |
| 2015-10-01 – 2015-12-31 | 1943876 | USD | 20170209 | Open filing evidence |
| 2015-04-01 – 2015-12-31 | 6720155 | USD | 20170209 | Open filing evidence |
| 2015-07-01 – 2015-09-30 | 2696507 | USD | 20161109 | Open filing evidence |
| 2015-04-01 – 2015-09-30 | 4776279 | USD | 20161109 | Open filing evidence |
| 2014-04-01 – 2015-03-31 | 5015246 | USD | 20170614 | Open filing evidence |
Abbreviated New Drug Applications
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=eltp:AbbreviatedNewDrugApplicationsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2020-04-01 – 2021-03-31 | 25214582 | USD | 20210614 | Open filing evidence |
| 2020-10-01 – 2020-12-31 | 6046582 | USD | 20210216 | Open filing evidence |
| 2020-04-01 – 2020-12-31 | 20819051 | USD | 20210216 | Open filing evidence |
| 2019-04-01 – 2020-03-31 | 16994639 | USD | 20210614 | Open filing evidence |
| 2019-10-01 – 2019-12-31 | 4805113 | USD | 20210216 | Open filing evidence |
| 2019-04-01 – 2019-12-31 | 12299340 | USD | 20210216 | Open filing evidence |
| 2019-07-01 – 2019-09-30 | 4384987 | USD | 20191112 | Open filing evidence |
| 2019-04-01 – 2019-09-30 | 7494227 | USD | 20191112 | Open filing evidence |
| 2019-04-01 – 2019-06-30 | 3109240 | USD | 20190809 | Open filing evidence |
| 2018-04-01 – 2019-03-31 | 6568508 | USD | 20200630 | Open filing evidence |
| 2018-10-01 – 2018-12-31 | 2443966 | USD | 20200210 | Open filing evidence |
| 2018-04-01 – 2018-12-31 | 5474713 | USD | 20200210 | Open filing evidence |
| 2018-07-01 – 2018-09-30 | 1113049 | USD | 20191112 | Open filing evidence |
| 2018-04-01 – 2018-09-30 | 3030747 | USD | 20191112 | Open filing evidence |
| 2018-04-01 – 2018-06-30 | 1917698 | USD | 20190809 | Open filing evidence |
| 2017-04-01 – 2018-03-31 | 6458711 | USD | 20190621 | Open filing evidence |
| 2017-10-01 – 2017-12-31 | 2285454 | USD | 20190211 | Open filing evidence |
| 2017-04-01 – 2017-12-31 | 5111805 | USD | 20190211 | Open filing evidence |
| 2017-07-01 – 2017-09-30 | 1373581 | USD | 20181109 | Open filing evidence |
| 2017-04-01 – 2017-09-30 | 2826351 | USD | 20181109 | Open filing evidence |
Abbreviated New Drug Applications
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=ELTP:AbbreviatedNewDrugApplicationsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-04-01 – 2025-06-30 | 40211097 | USD | 20250814 | Open filing evidence |
| 2024-04-01 – 2025-03-31 | 84043929 | USD | 20250630 | Open filing evidence |
| 2024-10-01 – 2024-12-31 | 14364248 | USD | 20250213 | Open filing evidence |
| 2024-04-01 – 2024-12-31 | 52047656 | USD | 20250213 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 18880345 | USD | 20241114 | Open filing evidence |
| 2024-04-01 – 2024-09-30 | 37683408 | USD | 20241114 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 18803063 | USD | 20250814 | Open filing evidence |
| 2023-04-01 – 2024-03-31 | 56625128 | USD | 20250630 | Open filing evidence |
| 2023-10-01 – 2023-12-31 | 15538800 | USD | 20250213 | Open filing evidence |
| 2023-04-01 – 2023-12-31 | 38676061 | USD | 20250213 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 14157185 | USD | 20241114 | Open filing evidence |
| 2023-04-01 – 2023-09-30 | 23137261 | USD | 20241114 | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 8980076 | USD | 20240814 | Open filing evidence |
| 2022-04-01 – 2023-03-31 | 34155114 | USD | 20240701 | Open filing evidence |
| 2022-10-01 – 2022-12-31 | 9250066 | USD | 20240214 | Open filing evidence |
| 2022-04-01 – 2022-12-31 | 25513551 | USD | 20240214 | Open filing evidence |
| 2022-07-01 – 2022-09-30 | 8585763 | USD | 20231114 | Open filing evidence |
| 2022-04-01 – 2022-09-30 | 16258671 | USD | 20231114 | Open filing evidence |
| 2022-04-01 – 2022-06-30 | 7672908 | USD | 20230814 | Open filing evidence |
| 2021-04-01 – 2022-03-31 | 32262117 | USD | 20230629 | Open filing evidence |
| 2021-10-01 – 2021-12-31 | 8974814 | USD | 20230214 | Open filing evidence |
| 2021-04-01 – 2021-12-31 | 24590044 | USD | 20230214 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 8558441 | USD | 20221114 | Open filing evidence |
| 2021-04-01 – 2021-09-30 | 15615230 | USD | 20221114 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 7056789 | USD | 20220815 | Open filing evidence |
| 2020-04-01 – 2021-03-31 | 25214582 | USD | 20220629 | Open filing evidence |
| 2020-10-01 – 2020-12-31 | 6046582 | USD | 20220214 | Open filing evidence |
| 2020-04-01 – 2020-12-31 | 20819051 | USD | 20220214 | Open filing evidence |
| 2020-07-01 – 2020-09-30 | 7399892 | USD | 20211115 | Open filing evidence |
| 2020-04-01 – 2020-09-30 | 14772469 | USD | 20211115 | Open filing evidence |
| 2020-04-01 – 2020-06-30 | 7372577 | USD | 20210816 | Open filing evidence |
Abbreviated New Drug Applications · Licensing
Statement Business Segments · Product Or Service
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=ELTP:AbbreviatedNewDrugApplicationsMember;srt:ProductOrServiceAxis=ELTP:LicensingMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-04-01 – 2025-06-30 | 433334 | USD | 20250814 | Open filing evidence |
| 2024-04-01 – 2025-03-31 | 2057850 | USD | 20250630 | Open filing evidence |
| 2024-10-01 – 2024-12-31 | 626117 | USD | 20250213 | Open filing evidence |
| 2024-04-01 – 2024-12-31 | 1640417 | USD | 20250213 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 655155 | USD | 20241114 | Open filing evidence |
| 2024-04-01 – 2024-09-30 | 1014300 | USD | 20241114 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 359145 | USD | 20250814 | Open filing evidence |
| 2023-04-01 – 2024-03-31 | 2504397 | USD | 20250630 | Open filing evidence |
| 2023-10-01 – 2023-12-31 | 747690 | USD | 20250213 | Open filing evidence |
| 2023-04-01 – 2023-12-31 | 2467844 | USD | 20250213 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 649315 | USD | 20241114 | Open filing evidence |
| 2023-04-01 – 2023-09-30 | 1720154 | USD | 20241114 | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 1070839 | USD | 20240814 | Open filing evidence |
| 2022-04-01 – 2023-03-31 | 4967541 | USD | 20240701 | Open filing evidence |
| 2022-10-01 – 2022-12-31 | 1451907 | USD | 20240214 | Open filing evidence |
| 2022-04-01 – 2022-12-31 | 4200888 | USD | 20240214 | Open filing evidence |
Abbreviated New Drug Applications · Manufacturing
Statement Business Segments · Product Or Service
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=ELTP:AbbreviatedNewDrugApplicationsMember;srt:ProductOrServiceAxis=ELTP:ManufacturingMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-04-01 – 2025-06-30 | 39777763 | USD | 20250814 | Open filing evidence |
| 2024-04-01 – 2025-03-31 | 81986079 | USD | 20250630 | Open filing evidence |
| 2024-10-01 – 2024-12-31 | 13738131 | USD | 20250213 | Open filing evidence |
| 2024-04-01 – 2024-12-31 | 50407239 | USD | 20250213 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 18225190 | USD | 20241114 | Open filing evidence |
| 2024-04-01 – 2024-09-30 | 36669108 | USD | 20241114 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 18443918 | USD | 20250814 | Open filing evidence |
| 2023-04-01 – 2024-03-31 | 54120731 | USD | 20250630 | Open filing evidence |
| 2023-10-01 – 2023-12-31 | 14791110 | USD | 20250213 | Open filing evidence |
| 2023-04-01 – 2023-12-31 | 36208217 | USD | 20250213 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 13507870 | USD | 20241114 | Open filing evidence |
| 2023-04-01 – 2023-09-30 | 21417107 | USD | 20241114 | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 7909237 | USD | 20240814 | Open filing evidence |
| 2022-04-01 – 2023-03-31 | 29187573 | USD | 20240701 | Open filing evidence |
| 2022-10-01 – 2022-12-31 | 7798159 | USD | 20240214 | Open filing evidence |
| 2022-04-01 – 2022-12-31 | 21312663 | USD | 20240214 | Open filing evidence |
Abbreviated New Drug Applications · License And Service
Statement Business Segments · Product Or Service
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=eltp:AbbreviatedNewDrugApplicationsMember;srt:ProductOrServiceAxis=us-gaap:LicenseAndServiceMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2020-04-01 – 2020-06-30 | 735338 | USD | 20200814 | Open filing evidence |
| 2019-04-01 – 2020-03-31 | 2468591 | USD | 20200630 | Open filing evidence |
| 2019-10-01 – 2019-12-31 | 1050392 | USD | 20200210 | Open filing evidence |
| 2019-04-01 – 2019-12-31 | 1447915 | USD | 20200210 | Open filing evidence |
| 2019-07-01 – 2019-09-30 | 215641 | USD | 20191112 | Open filing evidence |
| 2019-04-01 – 2019-09-30 | 397523 | USD | 20191112 | Open filing evidence |
| 2019-04-01 – 2019-06-30 | 181882 | USD | 20200814 | Open filing evidence |
| 2018-04-01 – 2019-03-31 | 1180812 | USD | 20200630 | Open filing evidence |
| 2018-04-01 – 2018-12-31 | 1017881 | USD | 20200210 | Open filing evidence |
| 2018-07-01 – 2018-09-30 | 306562 | USD | 20191112 | Open filing evidence |
| 2018-04-01 – 2018-09-30 | 682402 | USD | 20191112 | Open filing evidence |
| 2018-04-01 – 2018-06-30 | 375840 | USD | 20190809 | Open filing evidence |
| 2017-04-01 – 2018-03-31 | 1259705 | USD | 20190621 | Open filing evidence |
| 2017-04-01 – 2017-12-31 | 950856 | USD | 20190211 | Open filing evidence |
| 2017-04-01 – 2017-09-30 | 749228 | USD | 20181109 | Open filing evidence |
Abbreviated New Drug Applications · Manufactured Product Other
Statement Business Segments · Product Or Service
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=eltp:AbbreviatedNewDrugApplicationsMember;srt:ProductOrServiceAxis=us-gaap:ManufacturedProductOtherMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2020-04-01 – 2020-06-30 | 6637239 | USD | 20200814 | Open filing evidence |
| 2019-04-01 – 2020-03-31 | 14526048 | USD | 20200630 | Open filing evidence |
| 2019-10-01 – 2019-12-31 | 3754721 | USD | 20200210 | Open filing evidence |
| 2019-04-01 – 2019-12-31 | 10851425 | USD | 20200210 | Open filing evidence |
| 2019-07-01 – 2019-09-30 | 4169346 | USD | 20191112 | Open filing evidence |
| 2019-04-01 – 2019-09-30 | 7096704 | USD | 20191112 | Open filing evidence |
| 2019-04-01 – 2019-06-30 | 2927358 | USD | 20200814 | Open filing evidence |
| 2018-04-01 – 2019-03-31 | 5387696 | USD | 20200630 | Open filing evidence |
| 2018-04-01 – 2018-12-31 | 4456832 | USD | 20200210 | Open filing evidence |
| 2018-07-01 – 2018-09-30 | 806487 | USD | 20191112 | Open filing evidence |
| 2018-04-01 – 2018-09-30 | 2348345 | USD | 20191112 | Open filing evidence |
| 2018-04-01 – 2018-06-30 | 1541858 | USD | 20190809 | Open filing evidence |
| 2017-04-01 – 2018-03-31 | 5199006 | USD | 20190621 | Open filing evidence |
| 2017-04-01 – 2017-12-31 | 4160949 | USD | 20190211 | Open filing evidence |
| 2017-04-01 – 2017-09-30 | 2077123 | USD | 20181109 | Open filing evidence |
Business Segment
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=eltp:BusinessSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2019-04-01 – 2020-03-31 | 17994639 | USD | 20200630 | Open filing evidence |
| 2018-04-01 – 2019-03-31 | 7568508 | USD | 20200630 | Open filing evidence |
| 2017-04-01 – 2018-03-31 | 7458711 | USD | 20190621 | Open filing evidence |
| 2017-07-01 – 2017-09-30 | 1623581 | USD | 20171109 | Open filing evidence |
| 2017-04-01 – 2017-09-30 | 3326351 | USD | 20171109 | Open filing evidence |
| 2017-04-01 – 2017-06-30 | 1702770 | USD | 20170809 | Open filing evidence |
| 2016-04-01 – 2017-03-31 | 9637715 | USD | 20170614 | Open filing evidence |
| 2016-10-01 – 2016-12-31 | 2330649 | USD | 20170209 | Open filing evidence |
| 2016-04-01 – 2016-12-31 | 8287493 | USD | 20170209 | Open filing evidence |
| 2016-07-01 – 2016-09-30 | 2685698 | USD | 20171109 | Open filing evidence |
| 2016-04-01 – 2016-09-30 | 5956844 | USD | 20171109 | Open filing evidence |
| 2016-04-01 – 2016-06-30 | 3271146 | USD | 20170809 | Open filing evidence |
| 2015-04-01 – 2016-03-31 | 12498332 | USD | 20170614 | Open filing evidence |
| 2015-10-01 – 2015-12-31 | 2193876 | USD | 20170209 | Open filing evidence |
| 2015-04-01 – 2015-12-31 | 7303488 | USD | 20170209 | Open filing evidence |
| 2015-07-01 – 2015-09-30 | 2946507 | USD | 20161109 | Open filing evidence |
| 2015-04-01 – 2015-09-30 | 5109612 | USD | 20161109 | Open filing evidence |
| 2014-04-01 – 2015-03-31 | 5015246 | USD | 20170614 | Open filing evidence |
Business Segment · Branded Products Nda
Statement Business Segments · Product Or Service
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=eltp:BusinessSegmentMember;us-gaap:ProductOrServiceAxis=eltp:BrandedProductsNdaMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2017-04-01 – 2017-12-31 | 750000 | USD | 20180209 | Open filing evidence |
| 2017-04-01 – 2017-09-30 | 500000 | USD | 20171109 | Open filing evidence |
| 2016-04-01 – 2016-12-31 | 750000 | USD | 20180209 | Open filing evidence |
| 2016-04-01 – 2016-09-30 | 500000 | USD | 20171109 | Open filing evidence |
Business Segment · Generic Products Anda
Statement Business Segments · Product Or Service
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=eltp:BusinessSegmentMember;us-gaap:ProductOrServiceAxis=eltp:GenericProductsAndaMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2017-04-01 – 2017-12-31 | 5111805 | USD | 20180209 | Open filing evidence |
| 2016-04-01 – 2016-12-31 | 7537493 | USD | 20180209 | Open filing evidence |
New Drug Applications
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=eltp:NewDrugApplicationsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2020-04-01 – 2021-03-31 | 166167 | USD | 20210614 | Open filing evidence |
| 2020-04-01 – 2020-12-31 | 166167 | USD | 20210216 | Open filing evidence |
| 2019-04-01 – 2020-03-31 | 1000000 | USD | 20210614 | Open filing evidence |
| 2019-10-01 – 2019-12-31 | 250000 | USD | 20210216 | Open filing evidence |
| 2019-04-01 – 2019-12-31 | 750000 | USD | 20210216 | Open filing evidence |
| 2019-07-01 – 2019-09-30 | 250000 | USD | 20191112 | Open filing evidence |
| 2019-04-01 – 2019-09-30 | 500000 | USD | 20191112 | Open filing evidence |
| 2019-04-01 – 2019-06-30 | 250000 | USD | 20190809 | Open filing evidence |
| 2018-04-01 – 2019-03-31 | 1000000 | USD | 20200630 | Open filing evidence |
| 2018-10-01 – 2018-12-31 | 250000 | USD | 20200210 | Open filing evidence |
| 2018-04-01 – 2018-12-31 | 750000 | USD | 20200210 | Open filing evidence |
| 2018-07-01 – 2018-09-30 | 250000 | USD | 20191112 | Open filing evidence |
| 2018-04-01 – 2018-09-30 | 500000 | USD | 20191112 | Open filing evidence |
| 2018-04-01 – 2018-06-30 | 250000 | USD | 20190809 | Open filing evidence |
| 2017-04-01 – 2018-03-31 | 1000000 | USD | 20190621 | Open filing evidence |
| 2017-10-01 – 2017-12-31 | 250000 | USD | 20190211 | Open filing evidence |
| 2017-04-01 – 2017-12-31 | 750000 | USD | 20190211 | Open filing evidence |
| 2017-07-01 – 2017-09-30 | 250000 | USD | 20181109 | Open filing evidence |
| 2017-04-01 – 2017-09-30 | 500000 | USD | 20181109 | Open filing evidence |
New Drug Applications
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=ELTP:NewDrugApplicationsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-10-01 – 2025-12-31 | 0 | USD | 20260217 | Open filing evidence |
| 2025-04-01 – 2025-12-31 | 0 | USD | 20260217 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 0 | USD | 20251114 | Open filing evidence |
| 2025-04-01 – 2025-09-30 | 0 | USD | 20251114 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 0 | USD | 20250814 | Open filing evidence |
| 2024-04-01 – 2025-03-31 | 0 | USD | 20250630 | Open filing evidence |
| 2024-10-01 – 2024-12-31 | 0 | USD | 20260217 | Open filing evidence |
| 2024-04-01 – 2024-12-31 | 0 | USD | 20260217 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 0 | USD | 20251114 | Open filing evidence |
| 2024-04-01 – 2024-09-30 | 0 | USD | 20251114 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 0 | USD | 20250814 | Open filing evidence |
| 2023-04-01 – 2024-03-31 | 0 | USD | 20250630 | Open filing evidence |
| 2023-04-01 – 2023-12-31 | 0 | USD | 20250213 | Open filing evidence |
| 2023-04-01 – 2023-09-30 | 0 | USD | 20241114 | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 0 | USD | 20240814 | Open filing evidence |
| 2022-04-01 – 2023-03-31 | 0 | USD | 20240701 | Open filing evidence |
| 2020-04-01 – 2021-03-31 | 166167 | USD | 20220629 | Open filing evidence |
| 2020-04-01 – 2020-12-31 | 166167 | USD | 20220214 | Open filing evidence |
| 2020-04-01 – 2020-09-30 | 166167 | USD | 20211115 | Open filing evidence |
| 2020-04-01 – 2020-06-30 | 166167 | USD | 20210816 | Open filing evidence |
New Drug Applications · License And Service
Statement Business Segments · Product Or Service
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=eltp:NewDrugApplicationsMember;srt:ProductOrServiceAxis=us-gaap:LicenseAndServiceMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2020-04-01 – 2020-06-30 | 166167 | USD | 20200814 | Open filing evidence |
| 2019-04-01 – 2020-03-31 | 1000000 | USD | 20200630 | Open filing evidence |
| 2019-10-01 – 2019-12-31 | 250000 | USD | 20200210 | Open filing evidence |
| 2019-04-01 – 2019-12-31 | 750000 | USD | 20200210 | Open filing evidence |
| 2019-07-01 – 2019-09-30 | 250000 | USD | 20191112 | Open filing evidence |
| 2019-04-01 – 2019-09-30 | 500000 | USD | 20191112 | Open filing evidence |
| 2019-04-01 – 2019-06-30 | 250000 | USD | 20200814 | Open filing evidence |
| 2018-04-01 – 2019-03-31 | 1000000 | USD | 20200630 | Open filing evidence |
| 2018-04-01 – 2018-12-31 | 750000 | USD | 20200210 | Open filing evidence |
| 2018-07-01 – 2018-09-30 | 250000 | USD | 20191112 | Open filing evidence |
| 2018-04-01 – 2018-09-30 | 500000 | USD | 20191112 | Open filing evidence |
| 2018-04-01 – 2018-06-30 | 250000 | USD | 20190809 | Open filing evidence |
| 2017-04-01 – 2018-03-31 | 1000000 | USD | 20190621 | Open filing evidence |
| 2017-04-01 – 2017-12-31 | 750000 | USD | 20190211 | Open filing evidence |
| 2017-04-01 – 2017-09-30 | 500000 | USD | 20181109 | Open filing evidence |